ALXO | tickerfilter.com

Fundamental analysis

25%

Profitability 25%

Dept financing 2%

Liquidity 50%

Performance 24%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-9.63%

1 Month

11.92%

3 Months

-14.21%

6 Months

-71.01%

1 Year

-88.63%

2 Year

-84.26%

Key data

Stock price

$1.62

P/E Ratio

0.00

DAY RANGE

$1.59 - $1.70

EPS

$0.00

52 WEEK RANGE

$1.25 - $17.82

52 WEEK CHANGE

-$88.65

MARKET CAP

122.199 M

YIELD

N/A

SHARES OUTSTANDING

52.672 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/14/2024

BETA

1.61

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,830,527

AVERAGE 30 VOLUME

$1,393,759

Company detail

CEO: Jaume Pons
Region: US
Website: alxoncology.com
Employees: 40
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

ALX Oncology Holdings Inc. focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial. ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.

ALXO - ALX ONCOLOGY HOLDINGS INC